Tags

Type your tag names separated by a space and hit enter

Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials.
J Psychopharmacol 2004; 18(2):251-6JP

Abstract

The objective of this review was to determine the effectiveness, adverse effects and acceptability of folate in the treatment of depression. Electronic databases (Cochrane Controlled Trials Register and the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register) and reference lists were searched, and authors, experts and pharmaceutical companies contacted to identify randomized controlled trials that compared treatment with folic acid or 5'-methyltetrahydrofolic acid to an alternative treatment, for patients with a diagnosis of depressive disorder. Three randomized trials (247 participants) were included. Two studies assessed the use of folate in addition to other treatment, and found that adding folate reduced Hamilton Depression Rating Scale (HDRS) scores on average by a further 2.65 points [95% confidence interval (CI) 0.38-4.93]. Fewer patients treated with folate experienced a reduction in their HDRS score of less than 50% at 10 weeks (relative risk 0.47, 95% CI 0.24-0.92). The remaining study found no statistically significant difference when folate alone was compared with trazodone. The identified trials did not find evidence of any problems with the acceptability or safety of folate. The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression. It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.

Authors+Show Affiliations

Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Meta-Analysis
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Review
Systematic Review

Language

eng

PubMed ID

15260915

Citation

Taylor, Matthew J., et al. "Folate for Depressive Disorders: Systematic Review and Meta-analysis of Randomized Controlled Trials." Journal of Psychopharmacology (Oxford, England), vol. 18, no. 2, 2004, pp. 251-6.
Taylor MJ, Carney SM, Goodwin GM, et al. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol (Oxford). 2004;18(2):251-6.
Taylor, M. J., Carney, S. M., Goodwin, G. M., & Geddes, J. R. (2004). Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. Journal of Psychopharmacology (Oxford, England), 18(2), pp. 251-6.
Taylor MJ, et al. Folate for Depressive Disorders: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Psychopharmacol (Oxford). 2004;18(2):251-6. PubMed PMID: 15260915.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. AU - Taylor,Matthew J, AU - Carney,Stuart M, AU - Goodwin,Guy M, AU - Geddes,John R, PY - 2004/7/21/pubmed PY - 2004/10/9/medline PY - 2004/7/21/entrez SP - 251 EP - 6 JF - Journal of psychopharmacology (Oxford, England) JO - J. Psychopharmacol. (Oxford) VL - 18 IS - 2 N2 - The objective of this review was to determine the effectiveness, adverse effects and acceptability of folate in the treatment of depression. Electronic databases (Cochrane Controlled Trials Register and the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register) and reference lists were searched, and authors, experts and pharmaceutical companies contacted to identify randomized controlled trials that compared treatment with folic acid or 5'-methyltetrahydrofolic acid to an alternative treatment, for patients with a diagnosis of depressive disorder. Three randomized trials (247 participants) were included. Two studies assessed the use of folate in addition to other treatment, and found that adding folate reduced Hamilton Depression Rating Scale (HDRS) scores on average by a further 2.65 points [95% confidence interval (CI) 0.38-4.93]. Fewer patients treated with folate experienced a reduction in their HDRS score of less than 50% at 10 weeks (relative risk 0.47, 95% CI 0.24-0.92). The remaining study found no statistically significant difference when folate alone was compared with trazodone. The identified trials did not find evidence of any problems with the acceptability or safety of folate. The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression. It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency. SN - 0269-8811 UR - https://www.unboundmedicine.com/medline/citation/15260915/Folate_for_depressive_disorders:_systematic_review_and_meta_analysis_of_randomized_controlled_trials_ L2 - http://journals.sagepub.com/doi/full/10.1177/0269881104042630?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -